Pilot Study of RR-HNK in OCD

Last updated: October 7, 2025
Sponsor: Carolyn Rodriguez
Overall Status: Active - Recruiting

Phase

1/2

Condition

Panic Disorders

Anxiety Disorders

Obsessive-compulsive Disorder

Treatment

RR-HNK/Hydroxynorketamine

Placebo

Clinical Study ID

NCT06575075
57628
  • Ages 18-65
  • All Genders

Study Summary

The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Ages 18-65

  • Meet the criteria for OCD diagnosis

  • Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) oror had refused these treatments for individual reasons

  • Agree to the following lifestyle modifications: comply with requirements for fastingprior to --the infusion session, not enroll in any other interventional clinicaltrials during the duration of the study, and commit to medication study procedures.

  • Able to provide informed consent

Exclusion

Exclusion Criteria:

  • Allergy or hypersensitivity to ketamine

  • Any current or past medical/psychiatric condition that makes participation unsafe inthe opinion of the investigator or study physician

  • Pregnant or nursing, or able to become pregnant and are not practicing an effectivemeans of birth control

  • Lifetime history of deep brain stimulation

Study Design

Total Participants: 45
Treatment Group(s): 2
Primary Treatment: RR-HNK/Hydroxynorketamine
Phase: 1/2
Study Start date:
November 01, 2025
Estimated Completion Date:
November 30, 2029

Study Description

This protocol examines the safety and efficacy of 2 dosage levels of intravenous RR-HNK administration in individuals with OCD.

Connect with a study center

  • Stanford University School of Medicine

    Palo Alto 5380748, California 5332921 94305
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.